Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
(4) - EconoTimes)
KING OF PRUSSIA, Pa., May 31, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved, effective as of May 22, 2017 and May 30, 2017, the grant of inducement stock options to purchase an aggregate of 100,000 shares of the Company’s common stock to two new employees. These awards were granted pursuant to the Trevena, Inc. Inducement Plan as an inducement material to the new employees entering into employment with the Company, in accordance with NASDAQ Listing Rule 5635(c)(4).
The first stock option, for 47,500 shares, has an exercise price per share of $2.98, the closing stock price on May 22, 2017; the second stock option, for 52,500 shares, has an exercise price per share of $2.40, the closing stock price on May 30, 2017. Each option has a ten-year term and will vest with respect to one-fourth of the total number of shares subject to the option on each of first, second, third, and fourth anniversaries of the grant date.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO. Trevena also has discovered TRV250, in early clinical development for the treatment of migraine, and TRV734 for pain. The Company maintains an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Vice President, Corporate Strategy & Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
